Stock 300841 CHENGDU KANGHUA BIOLOGICAL PRODUCTS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Chengdu Kanghua Biological Products Co., Ltd.

Equities

300841

CNE100003Y57

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-04-23 pm EDT 		5-day change 1st Jan Change
59.68 CNY +4.72% Intraday chart for Chengdu Kanghua Biological Products Co., Ltd. +8.43% -23.03%
Apr. 23 Chengdu Kanghua Biological Products Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 01 Tranche Update on Chengdu Kanghua Biological Products Co., Ltd.'s Equity Buyback Plan announced on January 23, 2024. CI

Strengths

  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • The company's attractive earnings multiples are brought to light by a P/E ratio at 11.31 for the current year.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.
  • Considering the small differences between the analysts' various estimates, the group's business visibility is good.

Weaknesses

  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
CHENGDU KANGHUA BIOLOGICAL PRODUCTS CO., LTD. Stock Chengdu Kanghua Biological Products Co., Ltd.
-23.03% 1.05B -
CSL LIMITED Stock CSL Limited
-2.86% 87.37B
A-
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+3.95% 41.01B
A-
BIOGEN INC. Stock Biogen Inc.
-22.14% 28.08B
B-
UCB Stock UCB
+53.11% 24.72B
A
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-5.19% 17.47B
C
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-44.23% 11.69B
B
INCYTE CORPORATION Stock Incyte Corporation
-17.76% 11.6B
B-
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-13.96% 11.56B
D+
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
-0.22% 8.44B
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 300841 Stock
  4. Ratings Chengdu Kanghua Biological Products Co., Ltd.